Pfizer (NYSE:PFE) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Pfizer from “hold” to “buy,” though broader analyst sentiment remains “Hold,” with an average price target of $28.39.
• Pfizer shares opened at $27.69, near their 50-day and 200-day moving averages, with a market capitalization of approximately $157.8 billion.
• The company exceeded quarterly expectations, reporting $0.77 in EPS versus the $0.68 estimate and $15.03 billion in revenue, up 2.6% year over year.

Pfizer (NYSE:PFE - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Sunday, Wall Street Zen reports.

Other equities analysts have also issued reports about the company. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. UBS Group restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. HSBC upped their target price on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday. Finally, JPMorgan Chase & Co. reduced their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.39.

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $27.69 on Friday. The firm has a market capitalization of $157.82 billion, a P/E ratio of 36.43, a price-to-earnings-growth ratio of 1.86 and a beta of 0.34. Pfizer has a 1 year low of $23.58 and a 1 year high of $29.21. The firm's fifty day simple moving average is $26.35 and its 200 day simple moving average is $26.37. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $0.78 EPS. The business's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer will post 2.98 EPS for the current year.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the stock. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. Field & Main Bank bought a new stake in shares of Pfizer during the second quarter worth $27,000. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Finally, Bullseye Investment Management LLC bought a new position in Pfizer in the second quarter valued at about $28,000. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.